Recent advances of nanocarriers targeting tumor-associated macrophages in tumor therapy

doi:10.12092/j.issn.1009-2501.2018.07.018

Abstract

Abstract:

It is well known that tumor-associated macrophages (TAMs) play a vital role in the occurrence, development and metastasis of many tumors. Increasing evidences show that TAMs may be a promising target for tumor therapy and play an important role in future targeted treatment. Therefore, the design of TAMs-targeting nanocarriers which are able to achieve appropriate intratumoral biodistribution so as to effectively inhibit the growth of tumor has become a hot spot in recent years. In this review, the advantages of nanocarriers targeting TAMs are described. Since TAMs display a number of upregulated surface proteins (mannose receptor, folate receptor, cluster of differentiation 163, cluster of differentiation 11b, etc.), specific targeting using targeting ligands coupled to nanocarriers are discussed in the review, which may improve the ability of anti-tumor drug targeting TAMs.

Key words: tumor-associated macrophages, nanocarriers, targeted modification, tumor therapy

CLC Number:

R73
R966

ZHAO Xiaobin, YU Chenhuan, XIA Aixiao, YU Wenying, YU Bing. Recent advances of nanocarriers targeting tumor-associated macrophages in tumor therapy[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(7): 830-835.

References

［1］Jackute J,Zemaitis M,Pranys D,et al.Distribution of M1 and M2 macrophages in tumor islets and stroma in relation to prognosis of non-small cell lung cancer［J］. BMC Immunol, 2018, 19(1): 3.

［2］Yang L,Zhang Y.Tumor-associated macrophages: from basic research to clinical application［J］. J Hematol Oncol, 2017, 10(1) : 58.

［3］Erdogan S, Torchilin VP. Gadolinium-loaded polychelating polymer-containing tumor- targeted liposomes［J］. Method Mol Biol, 2017, 1522: 179-192.

［4］Fan Y, Yuan S, Huo M, et al. Spatial controlled multistage nanocarriers through hybridization of dendrimers and gelatin nanoparticles for deep penetration and therapy into tumor tissue［J］. Nanomedicine, 2017, 13(4): 1399-1410.

［5］陈芳君, 王增, 蔡鑫君, 等. 靶向肿瘤新生血管唑来膦酸阳离子隐形脂质体抗肿瘤作用的研究［J］. 中国临床药理学与治疗学, 2017, 22(1): 33-36.

［6］Huang L, Chaurasiya B, Wu D, et al. Versatile redox-sensitive pullulan nanoparticles for enhanced liver targeting and efficient cancer therapy［J］. Nanomedicine, 2018, 14(3): 1005-1017.

［7］Li S, Feng S, Ding L, et al. Nanomedicine engulfed by macrophages for targeted tumor therapy［J］. Int J Nanomed, 2016, 11: 4107-4124.

［8］Sosale NG, Spinler KR, Alvey C, et al. Macrophage engulfment of a cell or nanoparticle is regulated by unavoidable opsonization, a species-specific 'Marker of Self' CD47, and target physical properties［J］. Curr Opin Immunol, 2015, 35: 107-112.

［9］Chen L, Simpson JD, Fuchs AV, et al. Effects of surface charge of hyperbranched polymers on cytotoxicity, dynamic cellular uptake and localization, hemotoxicity, and pharmacokinetics in mice［J］. Mol Pharm,2017, 14(12): 4485-4497.

［10］Singh PK, Jaiswal AK, Pawar VK, et al. Fabrication of 3-O-sn-Phosphatidyl-L-serine Anchored PLGA nanoparticle bearing amphotericin B for macrophage targeting［J］. Pharm Res, 2018, 35(3): 60.

［11］Song M, Liu T, Shi C, et al. Bioconjugated manganese dioxide nanoparticles enhance chemotherapy response by priming tumor-associated macrophages toward M1-like phenotype and attenuating tumor hypoxia［J］. Acs Nano, 2016, 10 (3): 633-647.

［12］Peng H, Chen B, Huang W, et al. Reprogramming tumor-associated macrophages to reverse EGFR(T790M) resistance by dual-targeting codelivery of gefitinib/vorinostat［J］. Nano Lett, 2017, 17(12): 7684-7690.

［13］Blykers A, Schoonooghe S, Xavier C, et al. PET imaging of macrophage mannose receptor-expressing macrophages in tumor stroma using 18F-radiolabeled camelid single-domain antibody fragments［J］. J Nucl Med, 2015, 56(8): 1265.

［14］Zhan X, Jia L, Niu Y, et al. Targeted deleption of tumour associated macrophages by an alendronate-glucomannan conjugate for cancer immunotherapy［J］. Biomaterials, 2014, 35(38): 10046-10057.

［15］Zhao PF, Wang YH, Kang XJ, et al. Dual-targeting biomimetic delivery for antiglioma via remodeling tumor microenvironment and directing macrophage-mediated immunotherapy［J］. Chem Sci, 2018, 9: 2674-2689.

［16］Niu M,Valdes S,Naguib YW,et al.Tumor-associated macrophage-mediated targeted therapy of triple-negative breast cancer［J］.Mol Pharm,2016,13(6):1833-1842.

［17］Zeng Z, Dai S, Jiao Y, et al. Mannosylated protamine as a novel DNA vaccine carrier for effective induction of anti-tumor immune responses［J］. Int J Pharm, 2016, 506(1/2): 394-406.

［18］Locke LW, Mayo MW, Yoo AD, et al. PET imaging of tumor associated macrophages using mannose coated 64Cu liposomes［J］. Biomaterials, 2012, 33(31): 7785-7793.

［19］Zhu S, Niu M, O'Mary H, et al. Targeting of tumor-associated macrophages made possible by PEG-sheddable, mannose-modified nanoparticles［J］. Mol Pharm, 2013, 10(9): 3525-3530.

［20］Niu M, Naguib YW, Aldayel AM, et al. Biodistribution and in vivo activities of tumor-associated macrophage-targeting nanoparticles incorporated with doxorubicin［J］. Mol Pharm, 2014, 11(12): 4425-4436.

［21］Turk MJ,Waters DJ,Low PS.Folate-conjugated liposomes preferentially target macrophages associated with ovarian carcinoma［J］.Cancer Lett,2004,213(2):165-172.

［22］Poh S, Chelvam V, Ayala-López W, et al. Selective liposome targeting of folate receptor positive immune cells in inflammatory diseases ［J］. Nanomedicine, 2018, 14(3): 1033-1043.

［23］Penn CA,Yang K,Zong H,et al.Therapeutic impact of nanoparticle therapy targeting tumor-associated macrophages［J］.Mol Cancer Ther,2018,17(1):96-106.

［24］Liu Q,Xu N, Liu L,et al.Dacarbazine-loaded hollow mesoporous silica nanoparticles grafted with folic acid for enhancing anti-metastatic melanoma response［J］.ACS Appl Mater Interfaces,2017,9(26):21673-21687.

［25］Lisi L, Ciotti GM, Braun D, et al. Expression of iNOS, CD163 and ARG1 taken as M1 and M2 markers of micro glial polarization in human gliobla stoma and the surround in gnormal parenchyma［J］. Neurosci Lett, 2017, 645: 106-112.

［26］Zhang WJ, Wang XH, Gao ST, et al. Tumor-associated macrophages correlate with phenomenon of epithelial-mesenchymal transition and contribute to poor prognosis in triple-negative breast cancer patients［J］. J Surg Res, 2018, 222: 93-101.

［27］Ding D,Yao Y,Yang C,et al.Identification of mannose receptor and CD163 as novel biomarkers for colorectal cancer［J］.Cancer Biomark,2018,21(3):689-700.

［28］Kostine M, Briaire-de Bruijn IH, Cleven AHG, et al. Increased infiltration of M2-macrophages, T-cells and PD-L1 expression in high grade leiomyosarcomas supports immunotherapeutic strategies［J］. OncoImmunol, 2017, 7 (2): e1386828.

［29］Etzerodt A,Maniecki MB,Graversen JH,et al.Efficient intracellular drug-targeting of macrophages using stealth liposomes directed to the hemoglobin scavenger receptor CD163［J］.J Control Release,2012,160:72-80.

［30］Zhang QQ, Hu XW, Liu YL, et al. CD11b deficiency suppresses intestinal tumor growth by reducing myeloid cell recruitment［J］. Sci Rep, 2015, 3(5): 15948.

［31］Zhang QF, Yin WW, Xia Y, et al. Liver-infiltrating CD11b-CD27-NK subsets account for NK-cell dysfunction in patients with hepatocellular carcinoma and are associated with tumor progression［J］. Cell Mol Immunol, 2017, 14 (10): 819-829.

［32］Fang J, Ying H, Mao T, et al. Upregulation of CD11b and CD86 through LSD1 inhibition promotes myeloid differentiation and suppresses cell proliferation in human monocytic leukemia cells［J］. Nat Rev Cancer, 2017, 8: 85085-85101.

［33］Zhang M,Kim JA.Effect of molecular size and modification pattern on the internalization of water soluble β-(1→3)-(1→4)-glucan by primary murine macrophages［J］.Int J Biochem Cell Biol,2012,44(6):914-927.

［34］Zhang M,Gao Y,Caja K,et al.Non-viral nanoparticle delivers small interfering RNA to macrophages in vitro and in vivo［J］.PLoS One,2015,10:e0118472.

［35］Edgington-Mitchell LE, Wartmann T, Fleming AK, et al. Legumain is activated in macrophages during pancreatitis［J］. Am J Physiol Gastrointest Liver Physiol, 2016, 311(3): 548-560.

［36］Mai CW, Chung FF,Leong CO. Targeting legumain as a novel therapeutic strategy in cancers［J］. Curr Drug Targets, 2017, 18(11): 1259-1268.

［37］Li N, Liu Q, Su Q, et al. Effects of legumain as a potential prognostic factor on gastric cancers ［J］. Med Oncol, 2013, 30(3): 621.

［38］申龙,康立春,王德坤,等.肿瘤相关巨噬细胞中敲除Legumain可以通过促进肿瘤衰老来抑制肿瘤发展［C］.第十二届全国免疫学学术大会摘要汇编,2017.

［39］Shen L,Li H,Shi Y,et al.M2 tumour-associated macrophages contribute to tumour progression via legumain remodelling the extracellular matrix in diffuse large B cell lymphoma［J］.Sci Rep,2016,6:30347.

［40］Liu Z,Xiong M,Gong J,et al.Legumain protease-activated TAT-liposome cargo for targeting tumours and their microenvironment［J］.Nat Commun,2014,5:4280.

［41］Zhang X, Tian W, Cai X, et al. Hydrazinocurcumin encapsuled nanoparticles "re-educate" tumor-associated macrophages and exhibitAnti-tumor effects on breast cancer following STAT3 suppression［J］. PLoS One, 2013, 8(6): e65896.

［42］Liu M, Luo F, Ding C, et al. Dectin-1 activation by a natural product β-glucan converts immunosuppressive macrophages into an M1-like phenotype［J］. J Immunol, 2015, 195(10): 5055-5065.

［43］Ngambenjawong C, Pun SH. Multivalent polymers displaying M2 macrophage-targeting peptides improve target binding avidity and serum stability［J］. ACS Biomater Sci Eng, 2017, 3(9): 2050-2053.

［44］Zhou S, Zhang T, Peng B, et al. Targeted delivery of epirubicin to tumor-associated macrophages by sialic acid-cholesterol conjugate modified liposomes with improved antitumor activity［J］. Int J Pharm, 2017, 523(1): 203-216.

［45］Qian Y, Qiao S, Dai Y, et al. Molecular-targeted immunotherapeutic strategy for melanoma via dual-targeting nanoparticles delivering small interfering RNA to tumor-associated macrophages ［J］. ACS Nano, 2017, 11(9): 9536-9549.